logo
Queens Thai Chicken-and-Rice Favorite Is Expanding to Manhattan

Queens Thai Chicken-and-Rice Favorite Is Expanding to Manhattan

Eater03-06-2025
A Queens restaurant known for its Thai take on the Hainanese chicken and rice (khao man gai) is making its way into Manhattan. Eim Khao Mun Kai will be opening in the East Village on 129 Second Avenue, near St. Marks Place, as reported by EV Grieve. There doesn't seem to be an opening date yet; its Instagram notes that it'll keep expanding with 'more coming soon.' Eater has reached out for more information.
Owner Krianganan Rawiophap opened the restaurant in Elmhurst in 2014. Chef Srivaset Sajchaacharamontri's khao man gai features chicken poached in a gingery broth and served with ginger rice and cucumbers. This impending Manhattan location took over the space formerly home to ramen restaurant Misoya, which closed in April. Hamptons lobster pops up in NYC
Hamptons seafood restaurant Lunch Lobster Roll is in the middle of a summer pop-up at Tribeca steakhouse American Cut. The seasonal menu includes the happy hour special of two miniature lobster rolls, truffle fries or a Caesar salad, and a martini for $28, plus the regular lobster roll at dinnertime It'll run through the end of the summer. Fun cocktail pop-up alert
Fresh off its S&P Luncheonette residency, exciting weekend cocktail event A Pop-Up Called Pancakes is venturing into Brooklyn for its next pop-up. Co-founders Izzy Tulloch and Danielle De Block will serve drinks, plus the Instagram post promises pancakes. It takes place on Sunday, June 8, at the Long Island Bar from 9 p.m. to midnight. It's a kick-off to the international drinks trade show Bar Convent Brooklyn, which takes place from Tuesday, June 10 to Wednesday, June 11.
Sign up for our newsletter.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know

Yahoo

time24 minutes ago

  • Yahoo

Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Bruker (NASDAQ:BRKR) jumped 3.7%. Is now the time to buy Bruker? Access our full analysis report here, it's free. Generic Pharmaceuticals company Viatris (NASDAQ:VTRS) jumped 3.1%. Is now the time to buy Viatris? Access our full analysis report here, it's free. Research Tools & Consumables company Sotera Health Company (NASDAQ:SHC) jumped 3.1%. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) jumped 3.3%. Is now the time to buy Align Technology? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) jumped 3.1%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Zooming In On Bruker (BRKR) Bruker's shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock dropped 7.4% on the news that the company reported disappointing second-quarter results and lowered its full-year financial forecast, citing challenging market demand. The company's revenue for the quarter landed at $797.4 million, which missed analyst expectations. A key metric, organic revenue, which measures sales growth from a company's core operations, fell by 7.0%. Earnings per share (EPS), a measure of profitability, came in at $0.32, significantly below the consensus estimate of $0.42. In response to the weak performance, Bruker cut its full-year guidance, and now projected an organic revenue decline between 2% and 4%. Management pointed to decreased demand for life-science research instruments, especially from U.S. academic and biopharma customers, as the primary cause. The company also announced a cost-saving plan intended to reduce annual expenses. Bruker is down 45.9% since the beginning of the year, and at $31.80 per share, it is trading 55% below its 52-week high of $70.67 from September 2024. Investors who bought $1,000 worth of Bruker's shares 5 years ago would now be looking at an investment worth $723.25. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To Know
Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To Know

Yahoo

time24 minutes ago

  • Yahoo

Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Thermo Fisher (NYSE:TMO) jumped 3%. Is now the time to buy Thermo Fisher? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical (NASDAQ:ICUI) jumped 3.4%. Is now the time to buy ICU Medical? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company CONMED (NYSE:CNMD) jumped 3.1%. Is now the time to buy CONMED? Access our full analysis report here, it's free. Specialized Medical & Nursing Services company Pediatrix Medical Group (NYSE:MD) jumped 4.1%. Is now the time to buy Pediatrix Medical Group? Access our full analysis report here, it's free. Drug Development Inputs & Services company IQVIA (NYSE:IQV) jumped 3%. Is now the time to buy IQVIA? Access our full analysis report here, it's free. Zooming In On Pediatrix Medical Group (MD) Pediatrix Medical Group's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 4 months ago when the stock dropped 6.7% on the news that President Trump announced "reciprocal tariffs" on all US imports, set at a minimum rate of 10%. Markets reacted negatively to the announcement, reflecting deep concerns among investors about the broader economic implications. The tariffs were likely seen as a significant threat to global trade flows, with the potential to slow economic growth, drive up consumer prices, and spark retaliatory measures. Wedbush analyst Dan Ives captured the prevailing market anxiety, stating, "We would characterize this slate of tariffs as 'worse than the worst case scenario' the Street was fearing." His comment highlighted how the scope and severity of the tariffs far exceeded Wall Street's expectations, adding a new layer of uncertainty for businesses and investors. Pediatrix Medical Group is up 13.1% since the beginning of the year, but at $14.74 per share, it is still trading 14.5% below its 52-week high of $17.23 from February 2025. Investors who bought $1,000 worth of Pediatrix Medical Group's shares 5 years ago would now be looking at an investment worth $726.11. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know

Yahoo

time24 minutes ago

  • Yahoo

Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know

What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Health Insurance Providers company Centene (NYSE:CNC) jumped 3.1%. Is now the time to buy Centene? Access our full analysis report here, it's free. Testing & Diagnostics Services company RadNet (NASDAQ:RDNT) jumped 3.3%. Is now the time to buy RadNet? Access our full analysis report here, it's free. Healthcare Technology for Providers company Evolent Health (NYSE:EVH) jumped 3.2%. Is now the time to buy Evolent Health? Access our full analysis report here, it's free. Genomics & Sequencing company Illumina (NASDAQ:ILMN) jumped 3.1%. Is now the time to buy Illumina? Access our full analysis report here, it's free. Drug Development Inputs & Services company Charles River Laboratories (NYSE:CRL) jumped 3.1%. Is now the time to buy Charles River Laboratories? Access our full analysis report here, it's free. Zooming In On RadNet (RDNT) RadNet's shares are quite volatile and have had 15 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was about 2 months ago when the stock gained 5.2% on the news that the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. The Wall Street Journal said senior Iranian officials had signaled a willingness to restart stalled nuclear talks, on the condition that Washington refrain from joining Israel's ongoing strikes. This development triggered a significant decline in oil prices, easing inflation concerns. Also, it is possible some investors were buying the dip following the sell-off at the end of the previous week. RadNet is down 9.5% since the beginning of the year, and at $63.49 per share, it is trading 26.5% below its 52-week high of $86.38 from November 2024. Investors who bought $1,000 worth of RadNet's shares 5 years ago would now be looking at an investment worth $3,565. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store